After a Third Cancer Recurrence, a Hong Kong Patient Asked a US Colorectal Specialist One Question — and the Answer Changed Her Treatment Plan
- Medebound HEALTH
- Jun 9
- 13 min read
Introduction
When Sylvia (alias) received her third cancer diagnosis in fifteen years, she did not panic. By then, she had learned something that most patients never have to learn: how to hold fear and resolve in the same breath.
Sylvia is in her eighties and lives in Hong Kong. Over the previous decade and a half, she had survived two separate primary cancers — a bile duct cancer and a colorectal cancer — each treated with surgery, and in one case, followed by immunotherapy. She had weathered major operations, recovered quietly, and each time returned to her daily life. She was not someone who asked for second opinions casually. She trusted her doctors.
But late in 2025, a PET-CT scan and a rising tumour marker confirmed what everyone had feared: her colorectal cancer had returned at the surgical site. The question facing Sylvia and her family was no longer just whether she could survive another operation. It was what, if anything, should come next — and whether, at her age and with her complex medical history, any further treatment would do more good than harm.
"I had been through so much already. I just needed someone to tell me honestly what the best path forward was — not what was easiest, but what was right." — Sylvia
This is the story of how she sought a review from specialist affiliated with Dana-Farber Cancer Institute in the United States — and what that review revealed about the road ahead.
Fifteen Years of Medical History — and a New Crisis
Sylvia's cancer history is unusually complex. To understand the challenge she faced in late 2025, it helps to know what her body had already been through.
In 2010, she was diagnosed with moderately differentiated adenocarcinoma — in plain terms, a mid-grade malignant tumour — in her common bile duct, the tube that carries digestive fluid from the liver to the small intestine. She underwent extensive liver surgery, including removal of the right lobe of the liver and the caudate lobe (a small segment nestled against the back of the liver), along with the bile duct itself and surrounding lymph nodes. The surgical margins were clear of cancer, but the tumour had grown close — just one millimeter from the edge of the liver tissue.
Five years later, in 2015, imaging detected a recurrence in liver segment 4 — one of the eight anatomical sections of the liver — along with a separate small tumour in the rectum. Both were removed surgically. The rectal finding was a carcinoid (a slow-growing neuroendocrine tumor), which was confined to the inner lining and did not invade surrounding structures. Post-operative treatment with pembrolizumab (Keytruda) — an immunotherapy drug that helps the immune system recognise and attack cancer cells — was administered.
In early 2024, Sylvia presented with intermittent blood in the stool and anemia. Colonoscopy and imaging identified a new two-centimetre tumor at the hepatic flexure — the bend of the colon near the liver — which was confirmed as transverse colon adenocarcinoma (T3N1a): in plain terms, a moderately advanced colon cancer that had grown through the bowel wall and spread to one nearby lymph node. She underwent laparoscopic right hemicolectomy — a minimally invasive procedure to remove the right side of the colon — with negative surgical margins. For reasons documented in her case file, no adjuvant (post-operative) chemotherapy was administered at that time.
The 2024 tumor was tested for microsatellite instability (MSI) — a molecular marker that determines whether immunotherapy drugs would be effective. The result was microsatellite stable (MSS), with a low tumour mutation burden (TMB) of 4 mutations per megabase. In plain terms, the tumour's genetic profile meant that immunotherapy agents like pembrolizumab were unlikely to work for this cancer, and a KRAS G12V mutation — a change in one of the cancer's driver genes — ruled out the use of certain targeted antibody therapies including cetuximab and panitumumab.
Surveillance continued throughout 2024 and into 2025. Blood markers and scans were largely stable. Then, in late 2025, a PET-CT revealed new metabolic activity — in plain terms, signs of increased energy use consistent with cancer — at the anastomosis (the surgical reconnection site in the colon) and in the right mesentery (the fatty tissue supporting the intestines). Combined with a newly positive ctDNA result (circulating tumour DNA, a blood test that can detect fragments of cancer DNA) and a rising CEA level (carcinoembryonic antigen, a protein that rises when certain cancers are active), the picture was clear. Biopsy confirmed: the colorectal cancer had recurred.
In January 2026, Sylvia underwent laparoscopic resection of the recurrent lesions. Pathology confirmed recurrent colorectal adenocarcinoma at the anastomosis, with serosal penetration — meaning the tumour had grown through the outermost layer of the bowel wall. Surgical margins were clear, and fourteen nearby lymph nodes were negative. Immunohistochemistry was consistent with colorectal cancer, distinct from her earlier bile duct disease.
Now, following her second operation for colorectal recurrence, Sylvia and her family were faced with a critical question: what comes next?
Why the Family Decided to Seek a Specialist Review
Sylvia's family had several specific concerns that her local oncology team had not yet fully resolved.
The first was adjuvant therapy. Sylvia had not received chemotherapy after her initial 2024 colon cancer surgery, and now the cancer had recurred. The question — whether she should receive post-operative chemotherapy this time, and if so, which regimen — was pressing. Given her age, her cardiac history (including a coronary stent and left bundle branch block, a type of electrical conduction delay in the heart), her insulin-dependent diabetes, and her kidney function, the risks of chemotherapy were real and needed to be weighed carefully.
The second concerned surveillance. Her local team had been monitoring ctDNA — circulating tumour DNA in the blood — alongside CEA and PET-CT scans. But she had also read that not all cancer centres relied on ctDNA in the same way, and the family was uncertain whether this approach aligned with current international guidelines.
The third question was more philosophical: was there anything beyond conventional chemotherapy — vitamins, supplements, or other agents — that the evidence supported?
"We wanted to make sure every option had been considered. With everything she had been through, we owed her that." — Sylvia's family
Through Medebound HEALTH's cross-border consultation service, the family submitted Sylvia's complete medical records — including imaging, pathology reports, genetic testing results, surgical notes, and current medications — for review by a specialist gastrointestinal oncologist in the United States.
How the Second-Opinion Process Worked
The records submitted to Medebound HEALTH included Sylvia's full disease course from 2010 onwards: operative reports from five surgeries across fifteen years, pathology results from each procedure, genetic testing panels from both the 2016 and 2024 tumors, serial CEA and ctDNA blood results, multiple PET-CT reports, echocardiography findings, medication list, and the December 2025 and January 2026 investigations surrounding the recurrence and resection.
The case was reviewed by Dr. Mercer (alias), a board-certified medical oncologist with more than two decades of specialist experience in gastrointestinal cancers, with a particular focus on colon, rectal, and hepatobiliary malignancies. Dr. Mercer (alias) was currently appointed at Dana-Farber Cancer Institute, a comprehensive cancer treatment centre affiliated with Harvard Medical School, and holds a faculty position at Harvard Medical School as Professor of Medicine. Dr. Mercer (alias) leads the national CALGB 80702 clinical trial in partnership with the National Cancer Institute, and his research focuses specifically on the molecular mechanisms that influence response to treatment in colorectal cancer.
The second-opinion report was delivered as a detailed written document, addressing each of the family's specific clinical questions in sequence, with explanations of the reasoning behind each recommendation.
If you have received a complex diagnosis and would like a specialist review from a US oncologist, Medebound HEALTH's team can guide you through every step of the process at no cost.
What the Specialist Review Found
Dr. Mercer (alias) reviewed Sylvia's case in its full context — not merely the most recent recurrence, but the entire fifteen-year arc of her cancer history — and provided a structured analysis of the key clinical decisions.
1. Were the two colorectal cancers the same disease?
One significant finding in the specialist's review was a clarification about the nature of Sylvia's cancers. Because she had previously had cholangiocarcinoma (bile duct cancer) and the 2015 liver recurrence appeared to be a return of that disease, there was a question about whether the 2024 colon cancer might also be linked. Dr. Mercer was clear on this point: based on the immunohistochemistry profile (the pattern of proteins expressed by the cancer cells) and the molecular testing, the 2024 and 2026 colorectal cancers were distinct from the earlier bile duct disease. Although both the 2016 and 2024 tumours carried a KRAS G12V mutation — a common driver gene change in colorectal cancer — the other molecular alterations differed between the two cancers. This was consistent with two independent primary cancers rather than a single metastatic process.
In plain terms: Sylvia had not had one cancer spreading repeatedly. She had survived multiple separate cancers — an important distinction that affected how her ongoing management should be framed.
2. Should adjuvant chemotherapy be given — and could she tolerate it?
The central question for Sylvia's family was whether she should receive post-operative chemotherapy, given that she had not received it after her 2024 surgery, and cancer had subsequently recurred.
Dr. Mercer's view was unambiguous: adjuvant therapy was warranted. Specifically, he recommended either CAPOX (also called XELOX — a combination of oxaliplatin given by intravenous infusion and capecitabine, an oral chemotherapy tablet) or FOLFOX (a combination of oxaliplatin, leucovorin, and fluorouracil, all given intravenously) for a minimum of three months, and ideally six months. Both regimens are established standards for adjuvant treatment of colorectal cancer following curative-intent surgery.
On the question of whether Sylvia's age made chemotherapy too risky, Dr. Mercer was equally direct: age alone is not a determining factor. What matters is performance status and functional status — in plain terms, how independently a patient is living and functioning day to day. At the time of the review, Sylvia was ambulatory with only mild post-operative pain, which was an encouraging baseline.
For patients whose functional status makes the full CAPOX or FOLFOX regimen difficult to tolerate, Dr. Mercer offered an alternative: six months of fluoropyrimidine monotherapy — either oral capecitabine or intravenous 5-fluorouracil with leucovorin. This approach carries somewhat less risk of side effects, including peripheral neuropathy (nerve tingling or numbness in the hands and feet, a common side effect of oxaliplatin), but offers a modestly lower statistical reduction in recurrence risk compared to the combination regimens.
He also addressed a practical concern: what if Sylvia could not complete the full course? His answer was reassuring. Evidence from randomised trials suggests that three months of therapy may be nearly as effective as six months for many patients. And if treatment becomes intolerable mid-course, dose reductions or early discontinuation are legitimate clinical decisions — not failures. Even a partial course is likely better than no treatment at all.
3. How should she be monitored going forward?
Sylvia's local team had been using ctDNA — circulating tumour DNA detected in a blood sample — as part of her surveillance protocol. Dr. Mercer (alias) addressed this directly: ctDNA surveillance is not currently recommended in NCCN (National Comprehensive Cancer Network) guidelines — the leading US clinical guidelines for oncology — and he personally does not favour it as a standard monitoring tool. While some oncologists use it, he noted, the evidence base for routine ctDNA surveillance in colorectal cancer is still evolving.
His recommended surveillance schedule was specific: CEA testing every three months for the first two years following surgery, then every six months through to five years. Imaging (CT scan) every six months for the first two to three years, then annually through to five years. PET-CT scans should not be used for routine surveillance — only if a CT scan identifies a finding that cannot be clearly characterised, or if CEA rises without a corresponding CT abnormality.
Test | Frequency (Years 1–2) | Frequency (Years 3–5) |
CEA blood test | Every 3 months | Every 6 months |
CT/imaging scan | Every 6 months | Annually |
PET-CT | Only if CT scan is inconclusive, or CEA rises without CT finding | Same |
ctDNA | Not routinely recommended | Not routinely recommended |
4. What about supplements or complementary approaches?
The family had asked specifically about vitamin supplements and berberine — a plant-derived compound that has attracted interest in cancer research — citing recent published studies. Dr. Mercer (alias) was measured in his response: the current body of evidence does not support the use of vitamin supplements as a means of reducing colorectal cancer recurrence. Most data show no benefit.
The one exception is vitamin D. There is some evidence suggesting that correcting vitamin D deficiency may be beneficial, and Dr. Mercer (alias) recommended checking Sylvia's vitamin D level and supplementing if it is found to be insufficient. This is a low-risk, evidence-informed step that her local team could incorporate into routine monitoring.
On the question of whether the mesenteric lesion seen on the December 2025 PET-CT had been fully resected during the January 2026 surgery, Dr. Mercer (alias) noted that the clinical assumption — that both lesions were addressed together as part of the same operative field — was reasonable. He recommended continuing with the surveillance plan outlined above, which would detect any residual disease in subsequent scans.
Clinical Comparison: Original Management vs. Specialist Review Findings
Aspect | Original treating team (Hong Kong) | Specialist review (Dana-Farber) |
Adjuvant therapy after 2024 surgery | None administered | Recommended — adjuvant CAPOX or FOLFOX for 3–6 months based on functional status |
Age as a factor | Not documented as specifically addressed | Age alone does not determine suitability; performance and functional status are key |
Alternative regimen | Not offered | Fluoropyrimidine alone (IV 5-FU/leucovorin or capecitabine) considered viable with reduced toxicity |
Surveillance: ctDNA | ctDNA used as monitoring marker | ctDNA surveillance not favoured; not aligned with NCCN guidelines |
Surveillance: CEA & imaging | Monitored; PET-CT used routinely | CEA every 3 months for 2 years, then every 6 months to 5 years; imaging every 6 months for 2–3 years, then annually; PET-CT only if CT inconclusive or CEA elevated |
Vitamin / supplement use | Not documented | No evidence supports vitamins for reducing recurrence, except checking and correcting vitamin D deficiency |
Post-op chemotherapy decision | Patient and team still evaluating | Some treatment is better than none; partial course still reduces recurrence risk |
Individual results will vary. The outcome described reflects this patient's specific clinical circumstances. Speak with your own physician to understand what results may be realistic for your situation.
The Decision — Clarity After Uncertainty
For Sylvia and her family, the specialist review did not overturn the work of her Hong Kong oncology team. It supplemented it. The local team had performed the surgeries successfully — clear margins, no lymph node involvement — and had managed a genuinely difficult, multi-cancer history with skill. What the second opinion provided was a structured framework for the next phase: a clear recommendation on adjuvant therapy, a calibrated surveillance protocol, and honest guidance on what the evidence does and does not support.
The most significant shift was the recommendation for adjuvant chemotherapy. Her local team had not administered post-operative chemotherapy after the 2024 surgery, and the cancer had returned. The specialist review made a strong case for chemotherapy following the 2026 resection — and offered a tiered approach that accounted for Sylvia's age and comorbidities, including the option to start with a less intensive regimen and adjust based on tolerance.
"When you have been through what she has been through, you want to know that every reasonable option is on the table. The specialist review gave us that confidence." — Sylvia's family
With the specialist's written report in hand, the family returned to Sylvia's oncology team in Hong Kong for a structured discussion. The report was used as a reference document — not a directive — to support a shared decision-making conversation about which regimen, at which dose and duration, best suited Sylvia's current condition.
Like Sylvia's family, if you are weighing a significant treatment decision for a colorectal cancer diagnosis and want specialist input from a US oncologist, Medebound HEALTH can help.
Where Things Stand — and What the Road Ahead Looks Like
As of the time of writing, Sylvia had recently completed her January 2026 surgical resection. Her post-operative CEA had fallen to 2.0 ug/L (within the normal range of below 5.0 ug/L) by early February 2026, a positive early indicator. She was recovering from surgery with only mild pain, and her cardiac markers — which had shown a transient elevation in the peri-operative period — had been closely monitored and were trending downward.
The next step, based on the specialist's recommendation, was for Sylvia's local oncology team to assess her functional status in the weeks following surgery and make a decision about initiating adjuvant chemotherapy — most likely either a reduced-intensity FOLFOX or CAPOX protocol, or fluoropyrimidine monotherapy if the combination was considered too demanding given her overall health.
Her surveillance schedule was to be structured according to the specialist's protocol: CEA every three months, CT imaging every six months for the first two years, with PET-CT reserved for cases where the routine scans raised unresolved questions.
Vitamin D levels were to be checked and supplemented if deficient.
The overall picture — while requiring ongoing vigilance — was one of careful, evidence-based management of a patient whose history demanded exactly that level of attention.
What Sylvia's Story Teaches Us About Second Opinions
Several lessons emerge from this case that are relevant to any patient navigating a complex or recurring cancer diagnosis.
Post-operative chemotherapy decisions deserve expert scrutiny. The decision not to administer adjuvant therapy is a clinical choice — and one that can have lasting consequences. When cancer recurs following a surgery where adjuvant therapy was not given, a specialist review can help reframe the decision for subsequent treatment.
Age is not a disqualification. A patient in their eighties with a complex cardiac and metabolic history can still be a candidate for meaningful adjuvant treatment. Functional status — not chronological age — is what determines what is appropriate.
Surveillance protocols are not universal. The use of ctDNA as a monitoring tool illustrates how practices can vary across healthcare systems, sometimes ahead of the evidence base. Understanding what current international guidelines recommend — and why — can help patients and families make better-informed decisions about ongoing monitoring.
A second opinion is not a rejection of your treating physician. In Sylvia's case, the specialist review confirmed much of what her local team had already done well. Its value lay in adding structure and specificity to the next phase of management, not in contradicting prior care.
Even partial treatment can be better than none. For older or frailer patients who may not be able to complete a full chemotherapy course, the evidence from randomised trials suggests that a partial course still meaningfully reduces recurrence risk. This is an important piece of information for patients who may be deterred from treatment by concerns about side effects.
How Medebound HEALTH Connects International Patients to Top U.S. Cancer Experts
Medebound HEALTH is a U.S.-based medical coordination service that facilitates second opinions from independent U.S.-licensed physicians affiliated with leading cancer centers such as MD Anderson, Mayo Clinic, Memorial Sloan Kettering and Johns Hopkins. Since 2016, the service has supported 3000+ international patients, primarily from Asia, seeking expert input before major oncology decisions.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Is a Second Opinion Right for Your Situation?
If you or someone in your family has received a diagnosis that feels uncertain, a treatment plan that raises questions, or a disease that has returned or changed—you do not have to navigate that alone.
A 20-minute, no-obligation case review with a Medebound HEALTH Advisor will help you understand whether a specialist review is appropriate for your situation, which type of specialist would be most relevant, and what the process involves, step by step. There is no pressure and no commitment. The conversation begins with your questions.
Disclaimer
We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician. The service is independently operated by Medebound HEALTH and is not provided, partnered, or affiliated with any hospital center as an institution.
